ArticleFuture oncology (London, England)2024
The impact of body mass index on the progression-free survival of CDK 4/6 inhibitors in metastatic breast cancer patients.
Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Association between obesity and outcomes of first-line CDK4/6 inhibitor therapy in metastatic breast cancer: a multicenter real-world study.Scientific reports · 2026Article
- Article
- Association Between Body Mass Index and Clinical Outcomes of CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer: A Real-World Cohort Study.Journal of clinical medicine · 2026Article
- Review
- Alternate actions of CDK4/6 inhibitors beyond cell cycle blockade: unexplored roles in therapy resistance.Cancer metastasis reviews · 2025Review
- The impact of body mass index on the efficacy of CDK4/6 inhibitors in patients with metastatic breast cancer.Annals of medicine · 2025Article
- Impact of Body Composition on Progression-Free Survival in Patients with Metastatic Breast Cancer Treated with Ribociclib.Current oncology (Toronto, Ont.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.